bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P4-09-01: Poly (ADP-ribose) Polymerase-1 mRNA Expression in Human Breast Cancer: Correlations with Subtypes and Prognostic Impact
Authors: Gonçalves A , Finetti P , Gilabert M , Sabatier R , Borg J-P , Viens P , Birnbaum D , Bertucci F. 
Published: April 2011

Abstract
Introduction: Although poly(ADP-ribose) polymerase-1 (PARP1) inhibition is a recent promising therapy in breast cancer, PARP1 expression in this disease is not known.
Methods. Using DNA microarray and array-based comparative genomic hybridization (arrayCGH), we examined PARP1 mRNA expression and copy number alterations in 326 invasive breast cancer samples and normal breast samples. A meta-analysis was performed on a large public retrospective gene expression dataset (n= 2,485) to analyze correlation between PARP1 mRNA expression and molecular subtypes and clinico-pathological parameters.
Results. PARP1 was overexpressed in 58% of cancers, and its expression was heterogeneous between tumors. ArrayCGH data revealed an association between mRNA overexpression and gain/amplification at the PARP1 locus (p&lt;1.0E-8). Meta-analysis showed that PARP1 expression was higher in basal breast cancers (p&lt;1.0E-72), but overexpression was also found in other subtypes. PARP1 expression correlated with high grade, medullary histological type, tumor size and worse metastasis-free survival (HR=1.12 [1.04-1.22]; p=0.004). In multivariate analysis, PARP1 expression had an independent prognostic value, which was restricted to patients untreated with any adjuvant chemotherapy.
Univariate and multivariate analyses in MFS in patients untreated with systemic adjuvant chemotherapy
Conclusion. These data demonstrate overexpression of PARP1 in a large number of breast cancers and its association with reduced metastasis-free survival. These results further support the development of PARP inhibitors in basal subtype but also potentially in other breast cancer subtypes.

Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-09-01.
Abstract P4-09-06: Breast Cancer Prognosis Is Inherited Independently of Patient, Tumor and Treatment Characteristics
Authors: Rapiti E , Hartman M , Usel M , Benhamou S , Schaffar R , Neyroud-Caspar I , Czene K , Vlastos G , Chappuis PO , Bouchardy C , Verkooijen H. 
Published: April 2011

Abstract
Fondation Jean Dausset, Paris, France; Karolinska Institute, Stockolm, Sweden; Geneva University Hospitals, Switzerland Introduction: Several studies have suggested that survival of breast cancer is inherited, but none has assessed if this observation is linked to shared tumor characteristics or type of treatment. We studied the association of survival among first-degree relatives (FDRs) with breast cancer, taking into account characteristics of patients, tumors and treatments. Methods: In the population-based Geneva Breast Cancer Registry, we identified 162 pairs of FDRs diagnosed with breast cancer. Based on the breast cancer specific survival status of their proband (i.e. the mother or older sister), we categorized FDRs into poor, medium and good familial survival risk groups. We compared patient, tumor and treatment characteristics between categories and calculated standardized mortality ratios (SMRs) and adjusted disease specific mortality for each group. Results: Breast cancer patients in the poor familial survival risk group were more likely to be diagnosed at later stages than those in the good familial survival risk group. Similarly, they had higher SMRs than those in the medium and good survival risk groups (18.7, 95% Confidence Interval [CI]: 9.4-33.5 versus 16.5 95% CI: 7.6-31.4 and 9.4, 95% CI: 3.4-20.3, respectively). After adjustment for prognostic factors, women in the poor familial survival risk group were almost five times more likely to die of breast cancer than those in the good survival risk group (adjusted Hazard Ratio 4.8, 95% CI: 1.4-16.4).
Conclusion: This study shows that breast cancer prognosis clusters within families, and suggests that the hereditary component is independent of patient, tumor characteristics and type of treatment.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-09-06.
Abstract P4-09-08: PTEN Protein Expression in Postmenopausal Steroid Receptor Positive Early Breast Cancer Patients Treated with Adjuvant Tamoxifen
Authors: Milovanovic ZM , Susnjar SV , Plesinac-Karapandzic VS , Juranic ZD , Tatic SB , Dzodic RR. 
Published: April 2011

Abstract
Background: Since one of possible causes of resistance to antiestrogen therapy in SR+BC patients is an alteration of PTEN (Phosphatase and Tensin homolog deleted on chromosome 10) signaling pathways, the aim of this study was to determine the PTEN protein expression in postmenopaual patients with steroid receptor (SR)+ breast cancer (BC) treated with adjuvant tamoxifen, to investigate the association of PTEN protein expression with tumor histology, size and grade, estrogen receptor (ER), progesteron receptor (PR) and human epidermal growth receptor 2 (HER2) statuses and disease outcome, as well.
Patients and methods: This was a retrospective analysis of 78 postmenopausal SR+BC patients treated for stage I/II with adjuvant tamoxifen. PTEN protein expression and ER, PR and HER2 status were determined using immunohistochemistry method.
Results: The distribution of PTEN protein expression according to tumor histology was as follows: PTEN+ status in 27/43 (62,8%) patients with ductal and in 26/35 (74,3%) patients with lobular carcinomas and PTEN-status in 16/43 (37,2%) patients with ductal and in 9/35 (25,7%) patients with lobular carcinomas. Disease relapse was observed in 38/78 pateints: 14/53 (26.4%) of PTEN+BC subgroup and 24/25 (96%) of PTEN-BC subgroup. There were no significant association between PTEN protein expression and tumor histology, size and grade, and ER, PR and HER2 expression, as well. Patients with PTEN-BC had significantly shorter disease-free interval and overall survival (for both Log rank test, P&lt;0.01) compared to PTEN+BC pateints.
Conclusion: Our results suggest that PTEN protein expression might be of prognostic significance in postmenopausal SR+ BC patients treated with ajduvant Tamoxifen.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-09-08.
Abstract P4-09-12: The Effect of Age on Breast Cancer Outcomes in Women with Her-2 Positive Breast Cancer: Results from the HERA Trial
Authors: Partridge AH , Gelber S , Piccart M , Focant F , Scullion M , Winer E , Gelber R 
Published: April 2011

Abstract
Background: Previous research has suggested that young age at diagnosis is an independent risk factor for breast cancer recurrence and death. However, young women are more likely to develop more aggressive subtypes of breast cancer and no prior studies have adequately controlled for Her-2/neu status or anti-Her-2 treatment. We sought to evaluate whether age is a prognostic factor in the HERA trial, which is a large randomized phase III trial of women with Her-2 positive early stage breast cancer who were randomized to receive trastuzumab (for one or two years) or observation following (neo)-adjuvant chemotherapy.
Methods: We used 2 year median follow-up data from the HERA trial and conducted Cox proportional hazards models. Age was dichotomized at ≥40 years versus &gt; 41 years to evaluate its prognostic effect on outcomes in women who received trastuzumab and those who did not. Only patients included in the 1-year trastuzumab and observation arms were included in the present analysis.
Results: Of the 1703 women randomized to one-year of trastuzumab and 1698 to observation, 722 (21%) were age 40 or younger at study entry. Younger women were more likely to have node negative (33% vs 37%), estrogen receptor (ER)-negative (56 % vs 49%), and progesterone receptor (PR)-positive disease (41% vs 32%). In separate Cox models controlling for T and N stage, grade, ER and PR status, chemotherapy, endocrine therapy, and menopausal status at randomization, disease-free survival (DFS) hazard ratios were consistent for women ≥40 years compared with &gt; 41 years old patients, regardless of whether they were assigned to observation or to receive trastuzumab. DFS were as follow: observation group: HR (younger/older) = 1.09, p-value = 0.62; trastuzumab group: HR (younger/older) = 1.05, p-value = 0.84. There was no statistically significant interaction between age and treatment (p=0.94).
Conclusions: In women with early stage Her-2/neu positive breast cancer in a large RCT, age was not an independent predictor of risk of early recurrence. Future research to investigate whether age is a predictor of later risk of recurrence or is a predictor among women with other tumor subtypes is warranted.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-09-12.
Abstract P4-09-17: Case-Matching Study Comparing Outcome of Unilateral and Synchronous Bilateral Breast Cancer
Authors: Nichol A , Yerushalmi R , Tyldesley S , Lesperance M , Bajdik C , Speers C , Gelmon K , Olivotto I. 
Published: April 2011

Abstract
Background: Several retrospective studies have demonstrated worse outcomes for patients with synchronous bilateral breast cancer (SBBC) compared to unilateral breast cancer. This study aimed to determine whether SBBC outcomes can be estimated accurately from the characteristics of the higher-risk cancer.
Material and Methods: In the province of British Columbia, Canada, women newly diagnosed with invasive breast cancer between 1989 and 2000, without metastatic or inflammatory presentation, were identified: 207 with SBBC (&lt; 2 months apart) and 15,497 with unilateral breast cancer. Their breast cancer-specific survival (BCSS) outcomes were compared. Using 10-year BCSS estimates, the higher-risk cancer of each SBBC was determined. The priority sequence of matching of the prognostic and predictive variables was: positive lymph node number, primary tumor size, age, grade, lymphovascular invasion status, estrogen receptor status, type of local therapy, margin status, treating clinic, diagnosis year and systemic therapy use. A software program was employed on the 15,497-case cohort to select three unilateral cases that matched the maximum number of variables for the higher-risk cancer of each SBBC case, thereby generating a matched 621-case unilateral cohort.
Results: At a median follow-up of 10.2 years, the 10-year BCSS was significantly lower for the SBBC cohort, 71% (95%CI 63 — 77) than for the 15,497-case unilateral cohort, 81.1% (95%CI 80.5 — 81.8) (p &lt; 0.001). However, the SBBC cohort had significantly higher median age and stage at presentation. After the matching, there was no significant difference for the eleven variables between the SBBC cohort and the 621-case unilateral cohort. The 10-year BCSS was 71% (95%CI 63-77) for the SBBC cohort and 74% (95%CI 69-77) for the matched 621-case unilateral cohort. Discussion: BCSS was similar between the SBBC cohort and the unilateral cohort matched to the higher-risk SBBC. Therefore, the outcome of women with SBBC is best estimated from their higher-risk cancer.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-09-17.
Abstract P4-10-06: 10-Years Results of Intraoperative Electron Radiotherapy (IOERT) in Boost Modality in Breast Cancer Patients Treated with Breast Conserving Surgery
Authors: Reitsamer R , Kopp M , Fastner G , Menzel C , Glueck S , Merz F , Kopp P , Deutschmann H , Sedlmayer F. 
Published: April 2011

Abstract
Introduction:
The aim of this nonrandomized study was to compare the ipsilateral breast tumor recurrence rates in patients with invasive breast cancer, who had been treated with breast conserving surgery and whole breast irradiation and conventional boost or intraoperative electron radiotherapy boost (IOERT).
Patients and Methods:
378 patients were included in the study, 188 patients in group 1 (conventional boost) and 190 patients in group 2 (IOERT boost). Patients were comparable with regard to age, menopausal status, tumor size, histological type, grading and axillary lymph node status. Included were patients with invasive breast cancer pT1 and pT2, N0, N1, N2, M0, and breast conserving surgery with clear margins &gt;3mm. Excluded were patients with DCIS only, patients with invasive breast cancers larger than pT2, patients after primary systemic therapy and patients with multicentric disease. All patients (group 1 and group 2) received postoperative whole breast irradiation of 51-56.1 Gy. Group 1 received postoperative electron boost irradiation of 12 Gy after whole breast irradiation and group 2 received one intraoperative electron boost of 9 Gy in a single fraction during surgery before whole breast irradiation. Results:
The 10-years actuarial rates of ipsilateral breast tumor recurrence (IBTR), true local recurrence (TLR), distant recurrence (DR) and disease free survival (DFS) were 7.1% (95%CI, 3.2-11.0%), 4.8% (95%CI, 1.5-8.0%), 14,2% (95%CI, 9.1-19.4%) and 82.4% respectively in group1 and 2.7% (95%CI, 0.0-5.9%, P=0.062), 0.7% (95%CI, 0.0-2.0%, P=0.016), 13.6% (95%CI, 5.0-22.2%, P=0.90) and 84.0% (P= 0.76) respectively in group 2.
Conclusion:
Patients treated with IOERT boost and whole breast irradiation achieve excellent local control rates at 10 years and exhibit statistically significant decreased true local recurrence rates compared to patients treated with whole breast irradiation and conventional electron boost.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-10-06.
Abstract P4-10-09: An Oncoplastic Surgical Planning Tool Based on Tumor Location Improves Breast Conservation Outcomes
Authors: Kaufman GJ , Clough KB , Oden S , Nos C , Safarti I. 
Published: April 2011

Abstract
OBJECTIVE
Oncoplastic Surgery is an evolving field in breast cancer surgery. Considerable variations in oncoplastic surgery (OPS) for breast conservation (BCS) have developed as the interest and utilization by both breast surgeons and plastic surgery teams continues to increase. Our goal is to assess the effectiveness of an oncoplastic surgical planning tool for BCS. The tool is a surgical atlas and guide that matches oncoplastic procedure recommendations for a specific tumor location.
BACKGROUND
Oncoplastic surgery for the treatment of breast cancer has been validated compared to standard BCS in terms of rate of re-excision, preservation of the natural breast shape, complications and 5-year local recurrence rates. Oncoplastic surgery incorporates plastic surgery techniques for the purpose of breast conservation. A bi-level OPS classification system and guide for patient selection was created to improve both patient outcomes and enable all breast surgeons to choose a safe and effective oncoplastic approach.
METHODS
This is a single institution prospective study of patients with breast cancer that had an oncoplastic level II procedure for breast conservation between 2005 and 2009 at the Paris Breast Center. The corresponding level II OPS technique was chosen for each patient based on the principals of patient selection and tumor location described in the atlas. A set of objective outcomes as well as an aesthetic evaluation was recorded based on tumor location and choice of procedure.
Results
A total of 151 patients met the criteria for performing a level II OPS for breast conservation based on the selection process outlined in the oncoplastic Atlas. The overall adherence rate for selection of procedure based on tumor location was 90%. The reexcision rate was 4% with greater then 80% of patients achieving a margin width exceeding .5cm and an average specimen weight of 144 grams. The conversion rate to mastectomy approached 12%. We found a good to excellent aesthetic outcome in 95% of evaluated patients. The rate of deformity in this level II OPS series was 0%. The early complication rate was 11% resulting in a delay of treatment for adjuvant therapy in less then 2% of patients.
Tumor Location and OPS Level II Procedure
Complications and Delay in Treatment
CONCLUSIONS
Adherence to the oncoplastic surgical guide resulted in an acceptable reexcision rate with the elimination of the risk of deformity for patients undergoing large volume resections for breast conservation. This initial assessment validates the efficacy of the atlas and provide surgeons with a reliable system to correctly choose the most appropriate oncoplastic procedure based on tumor location and avoids the complications associated with a one technique fits all approach for OPS.

Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-10-09.
Abstract P4-11-04: The Influence of Radiation on Survival in Patients with Triple Negative Stage II Breast Cancer
Authors: Hinton B , De Los Santos J , Keene K , Meredith R , Carpenter J , LoBuglio A , Falkson C , Krontiras H , Bland K , Wang C , Kim Y , Forero A. 
Published: April 2011

Abstract
Background: Prospective trials of locally advanced breast cancer patients treated with adjuvant radiation (RT) have demonstrated a survival advantage; however, use of postmastectomy RT in stage II patients is controversial. This study explores the possibility that patients with aggressive variant molecular subtypes [triple receptor negative (TN)] treated with modern chemotherapy, may experience a survival benefit from adjuvant RT.
Methods: Billing codes for all breast cancer patients treated with chemotherapy between 1/1998 and 5/2005 at the University of Alabama at Birmingham were reviewed to comprehensively capture all Stage II and III patients with intact data. Patient, tumor, and treatment related variables were recorded and patients were divided into 3 molecular subtypes based on receptor status: hormone receptor (HR) positive, Her2 negative; HR+/− , Her2+; and TN. Kaplan Meier curves to assess survival were performed by dividing the TN group into 2 groups: those who did or did not receive adjuvant RT.
Results: 409 patients with stage II-III disease with were identified. Out of this group, 81 patients had TN breast cancer (60 Stage II and 21 Stage III). RT data was known in 79 of these patients. Median age was 49 years. Median follow-up was 72 months. Thirty-seven stage II and 18 stage III patients received adjuvant RT. Of the stage II patients who received radiation, 25 underwent lumpectomy and 11 underwent mastectomy. Stage II patients who received adjuvant RT had a statistically significant improvement in DFS (p=0.03), and had a trend towards improvement in OS (p=0.07) when compared with those who did not receive adjuvant RT. There was no significant difference in survival for the stage III patients with use of RT, however numbers in this group were small. Conclusion: Adjuvant RT was associated with an improvement in DFS and a trend towards improvement in OS in patients with Stage II, TN breast cancers treated with modern chemotherapy.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-11-04.
Abstract P4-11-10: A Study of Intraoperative Radiotherapy with Electrons in Breast-Conserving Surgery in China: 3 Year Results
Authors: Zhou S , Sun C , Meng D , Shi W , Lv Q , Jing J , Zhao Y. 
Published: April 2011

Abstract
Background:The standard treatment for most localised breast cancer patients is the breast-conservating sugery followed by postoperative radiation worldwide. Preliminary studies of intraoperative radiotherapy with electrons(ELIOT) in selected patients, mainly in Europe since 1999, have shown good local control, less toxicity and satisfatory cosmetic apperance. However few studies have been conducted among non-western populations. To investigate the feasibility of ELIOT in China, we introduced ELIOT in selected early breast cancer patients. Risk of local relapse is the main outcome objective, toxicity and cosmetic results are also studied.
Patients and Methods:From June 2007 to May 2010, 51 patients diagnosed with unifocal breast carcinoma up to a diameter of 3cm received a wide excision of the primary tumor followed by a radiotherapy of 21Gy delivered to the breast tissue at the surface of the tumor bed, biologically equivalent to 58 to 60 Gy in standard fractionation.
The median age of the treated patients was 47 years, with 38/51(74.5%) patients younger than 50. 8 patients(15.7%) were found to have positive axillary I-nodes(six patients had one node involved, one patient had two and one had three positive nodes). Pathologic free margins ≥10 mm were obtained in all patients. Patients were evaluated semiannunally after surgery, and thereafter every 6 months for cosmetic results, complications and other events.
Results: After a follow-up from 4 to 36 months(median time12 months), 3 patients developed fat deliquescence, 16 patients showed wound edema and excess fluid and no one had incision infection or hematoma. Two patients developed local relapses. One was comfirmed unrecognised multi-focal cancer in other quadrants of the breast remain dormant. The other patient was confirmed ipsilateral positive axillary III-nodes and no relapse was found in the same quadrant. Neither contralateral breast cancer nor distant metastases were observed. No replase was found in patients aged &lt;50. Accodring to the JCRT standard, cosmetic result was excellent in 73.1% and 90.9% patients at one year and two year checkup respectively, and good was found in 15.4% and 9.1% patients.
Conclusion:The incidence of breast cancer remains to increase in China with the aging of society and changes of lifestyle, and the highest incidence is found in the age group 45-50 years.Our study suggested the toxicity and cosmetic evalution were good. Data on local control were encouraging, especially for those under 50. ELIOT of 21Gy was a well-tolerated treatment in early stage Chinese breast cancer patients. And further follow up is still needed.

Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-11-10.